Su Min Ha1, Jung Hwan Baek2, Young Jun Choi3, Sae Rom Chung3, Tae Yon Sung4, Tae Yong Kim5, Jeong Hyun Lee3. 1. Department of Radiology and Thyroid Center, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, 06973, Korea. 2. Department of Radiology and the Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. radbaek@naver.com. 3. Department of Radiology and the Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. 4. Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. 5. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Abstract
OBJECTIVE: Some authors have found little or no diagnostic benefit from repeated biopsy of benign thyroid nodules. However, to our knowledge, integration of Thyroid Imaging Reporting and Data System (TIRADS) guidelines with one biopsy for sufficient benign thyroid nodule diagnosis has not been previously described. We investigated malignancy rate and probability by using various malignancy stratification systems in initially biopsy-proven benign nodules and sought to determine their clinical relevance in management of benign thyroid nodules. METHODS: This retrospective study collected 6762 thyroid nodules from 6493 consecutive patients who underwent biopsy between January 2013 and December 2013. The initial biopsy with ≥1 year of follow-up was used as the gold standard for benign diagnosis. For our study purpose, we analyzed 2747 (57.0%, 2747 of 4822, 532 women, 2111 men; 229 malignant and 2518 benign) thyroid nodules diagnosed by initial biopsy with 28.2 ± 9.1 (range, 12-41) months of follow-up. We calculated the malignancy probability of thyroid nodules by using various malignancy risk stratification systems. RESULTS: The overall calculated thyroid malignancy rate was 8.3% (229 of 2747). Initially biopsy-proven benign nodules exhibited a ≤3.0% malignancy probability when assessed as "low suspicion" by Korean-TIRADS (K-TIRADS), "low suspicion" by the ATA guideline, and "very probably benign" by the French TIRADS guideline and gave a score of ≤3 by the web-based TIRADS. CONCLUSION: When initially biopsy-proven benign nodules exhibit a "low suspicion" US pattern and low malignancy probability, as stratified by various TIRADS guidelines, imaging surveillance instead of second biopsy is warranted. KEY POINTS: • One biopsy is sufficient for initially biopsy-proven benign nodules. • Repetitive biopsy is necessary for imaging-pathology mismatched nodules. • Scoring risk stratification permits personalized management.
OBJECTIVE: Some authors have found little or no diagnostic benefit from repeated biopsy of benign thyroid nodules. However, to our knowledge, integration of Thyroid Imaging Reporting and Data System (TIRADS) guidelines with one biopsy for sufficient benign thyroid nodule diagnosis has not been previously described. We investigated malignancy rate and probability by using various malignancy stratification systems in initially biopsy-proven benign nodules and sought to determine their clinical relevance in management of benign thyroid nodules. METHODS: This retrospective study collected 6762 thyroid nodules from 6493 consecutive patients who underwent biopsy between January 2013 and December 2013. The initial biopsy with ≥1 year of follow-up was used as the gold standard for benign diagnosis. For our study purpose, we analyzed 2747 (57.0%, 2747 of 4822, 532 women, 2111 men; 229 malignant and 2518 benign) thyroid nodules diagnosed by initial biopsy with 28.2 ± 9.1 (range, 12-41) months of follow-up. We calculated the malignancy probability of thyroid nodules by using various malignancy risk stratification systems. RESULTS: The overall calculated thyroid malignancy rate was 8.3% (229 of 2747). Initially biopsy-proven benign nodules exhibited a ≤3.0% malignancy probability when assessed as "low suspicion" by Korean-TIRADS (K-TIRADS), "low suspicion" by the ATA guideline, and "very probably benign" by the French TIRADS guideline and gave a score of ≤3 by the web-based TIRADS. CONCLUSION: When initially biopsy-proven benign nodules exhibit a "low suspicion" US pattern and low malignancy probability, as stratified by various TIRADS guidelines, imaging surveillance instead of second biopsy is warranted. KEY POINTS: • One biopsy is sufficient for initially biopsy-proven benign nodules. • Repetitive biopsy is necessary for imaging-pathology mismatched nodules. • Scoring risk stratification permits personalized management.
Authors: Victoriya S Chernyavsky; Beth-Ann Shanker; Tomer Davidov; Jessica S Crystal; Oliver Eng; Kareem Ibrahim; Jonathan Kwong; Stanley Z Trooskin Journal: Ann Surg Oncol Date: 2011-10-04 Impact factor: 5.344
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Chung-Che Charles Wang; Lyssa Friedman; Giulia C Kennedy; Hui Wang; Electron Kebebew; David L Steward; Martha A Zeiger; William H Westra; Yongchun Wang; Elham Khanafshar; Giovanni Fellegara; Juan Rosai; Virginia Livolsi; Richard B Lanman Journal: Thyroid Date: 2010-12-29 Impact factor: 6.568
Authors: Jin Young Kwak; Kyung Hwa Han; Jung Hyun Yoon; Hee Jung Moon; Eun Ju Son; So Hee Park; Hyun Kyung Jung; Ji Soo Choi; Bo Mi Kim; Eun-Kyung Kim Journal: Radiology Date: 2011-07-19 Impact factor: 11.105
Authors: Jin Young Kwak; Hyeryoung Koo; Ji Hyun Youk; Min Jung Kim; Hee Jung Moon; Eun Ju Son; Eun-Kyung Kim Journal: Radiology Date: 2009-12-17 Impact factor: 11.105
Authors: Lorenzo Scappaticcio; Pierpaolo Trimboli; Sergio Iorio; Maria Ida Maiorino; Miriam Longo; Laura Croce; Marcello Filograna Pignatelli; Sonia Ferrandes; Immacolata Cozzolino; Marco Montella; Andrea Ronchi; Renato Franco; Mario Rotondi; Giovanni Docimo; Katherine Esposito; Giuseppe Bellastella Journal: Front Endocrinol (Lausanne) Date: 2022-09-15 Impact factor: 6.055